Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
Abstract Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP) previously under development as a lipid‐modifying agent that reduces LDL‐cholesterol and increases HDL‐cholesterol in hypercholesterolemic patients. Anacetrapib demonstrates a long terminal half‐life and accumulates in...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Wiley
2019-12-01
|
| Ráidu: | Pharmacology Research & Perspectives |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1002/prp2.543 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
